Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Unexpected effect of MS drug

Researchers at Karolinska Institutet in Sweden have studied the mechanism of action of a drug used to treat multiple sclerosis. The results, which are published in the journal Nature Communications, show that the drug affects cells in the innate immune system and that there is an unexpected link between therapeutic effect and an increase in the production of reactive oxygen species.Multiple sclerosis (MS) is an autoimmune disease that affects the central nervous system. The tablet Tecfidera (dimethyl fumarate, DMF) was approved a few years ago, but the exact mechanism of action of the drug

Invitation to presentation of NCC’s interim report for January - June and the second quarter 2019

NCC’s interim report for January-June 2019 will be released on Friday, July 19. The report will be distributed and available on NCC’s website, www.ncc.se/ir, on or around 07:10 a.m. (CET). A conference call for media and capital markets representatives, will be held the same day between 09:00 and 10:00 a.m. (CET) hosted by NCC’s CEO Tomas Carlsson and CFO Susanne Lithander. The presentation will be held in English. It will be made available via audiocast on www.ncc.se/ir. Presentation material for the teleconference will be available at www.ncc.se/ir, on Friday, July 19 as of 08:30 a.

Invitation to webcast for the presentation of Lime Technologies’ Interim Report for January-June 2019

Lime Technologies’ Interim Report for January-June 2019 will be published on Friday, July 19, 2019, at 08:00 CEST.The same day at 10:30 CEST; analysts, investors, media and other interested parties are invited to attend a webcast where Lime’s CEO, Erik Syrén, and CFO, Magnus Hansson, will comment on the published report and answer questions. The presentation will be held in English. The presentation material will be available on Lime’s website . How to participate in the webcast? Use this link to

Interim report Q2 2019

Second quarter 2019  ● Incoming orders rose 2% to SEK 847 million (834)  ● Net sales rose 6% to SEK 848 million (802)  ● Operating profit was SEK 90 million (89)  ● EBITA stood at SEK 93 million (94)  ● Profit after tax rose 4% to SEK 69 million (67)  ● Earnings per share were SEK 3.01 (2.89)   January – June 2019  ● Incoming orders rose 6% to SEK 1,717 million (1,614)  ● Net sales rose 9% to SEK 1,694 million (1,559)  ● Operating profit rose 11% to SEK 189 million (170)  ● EBITA rose 9% to SEK 196 million (180)  ● Profit after tax rose 15% to SEK 147

#19-976 Correction #19-975 Listing of Derivatives at NGM

Issuer has been changes on ISIN XS2014475854.Information about various derivatives that will be listed at NGM. For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded

Significantly oversubscribed rights issue in Scandion Oncology

On July 9, 2019, the subscription period in Scandion Oncology A/S’s ("Scandion Oncology") rights issue of units ended. The interest in the rights issue was significant and the rights issue was subscribed to a total of approx. SEK 58.3 million (excl. guarantee commitments), corresponding to a subscription rate of approx. 199 percent. Through the rights issue, a total of 7,144,590 shares and 2,381,530 warrants of series TO 1 will be issued and Scandion Oncology will now be provided approx. SEK 29.3 million before issue costs. Settlement notes are expected to be sent out today, July 12, 2019.

Skanska signs additional contract for corporate office improvements in western USA for USD 51.1 M, about SEK 481 M

Skanska has booked an additional order with an existing client for improvements to their corporate office in the western USA. The incremental contract with our joint venture of Skanska Balfour Beatty is worth USD 102.2 M; Skanska’s contract value is USD 51.1 M, about SEK 481 M, which will be included in the US order bookings for the second quarter 2019.Construction is underway. Skanska is one of the leading construction and development companies in USA, specialized in building construction, civil infrastructure and developing commercial properties in select U.S. markets. Skanska USA had

Cyxone announce dosing of first volunteer in T20K’s first-in-human trial

Cyxone (publ.) a Swedish biotech in autoimmune diseases, today announced that the first healthy male volunteer has received the initial dose in its first-in-human, clinical phase I, trial with drug candidate T20K, in development for the treatment of multiple sclerosis (MS). The clinical phase I study is estimated to be concluded during the second half of 2019.The recruitment and screening of healthy male volunteers for Cyxone’s first-in-human trial with T20K was initiated in June of this year, following the approval from the relevant authorities in the Netherlands where the study site is

Notice of Extra General Meeting in Bambuser AB

The shareholders of Bambuser AB (publ), reg. no. 556731-3126, ("The Company") is hereby invited to attend the Extraordinary General Meeting on Friday, August 23, 2019 at. 16.00 CEST at Ramberg Lawyer's office at Jakobsbergsgatan 13 in Stockholm. Registration for the meeting starts at. 15.30.  Participation  Shareholders who wish to attend the meeting shall:  ·be entered in the share register kept by Euroclear Sweden AB on Saturday August 17, 2019 (note that since the record date is a Saturday, shareholders must be entered in the share register on Friday, August 16, 2019) and

Realheart summarizes the spring’s animal trials and tests automatic control

Realheart has concluded a series of eight short animal trials on sheep. The implantation technique for Realheart TAH has successively been developed and most of the earlier challenges have been resolved. During the spring’s trials a unique automatic control has been tested.The company has completed eight short pre-clinical animal trials on sheep. During the trials Realheart TAH has been adapted to the animal model through an adaptation of the surgical implantation technique, connections to the animal’s vessels and control of de-airing. During the final operation the animal breathed

Minutes of the Monetary Policy Meeting held on 2 July 2019

At the Monetary Policy Meeting on 2 July 2019, the Executive Board of the Riksbank decided to leave the repo rate unchanged at –0.25 per cent. The forecast for the repo rate is also unchanged and indicates that it will be increased again towards the end of the year or at the beginning of next year.The board members supported the picture of the economic outlook and inflation prospects described in the draft Monetary Policy Report. Economic activity in Sweden remains strong and inflation is close to the target of 2 per cent. They noted that economic development both in Sweden and abroad has

Diaverum, a leading renal care service provider, enters Morocco with partnership in Marrakech

Marrakesh, 12 July 2019 - Diaverum, the global renal care service provider with a presence across 19 countries, extends its activities to Morocco through a partnership with Centre d’Hémodialyse de Marrakech (CHM).Diaverum is pleased to announce its expansion into Africa, with a partnership with Centre d’Hémodialyse de Marrakech (CHM), a renal care centre founded in 1991 by Dr Idrissi Kaitouni, its leading Nephrologist. The partnership will expand Diaverum’s presence to 20 countries worldwide. Today, Morocco is a market with over 25,000 End Stage Renal Disease (ESRD) patients, a number which

ABB wins traction equipment orders to expand rail fleets in the US and Europe

Zurich, Switzerland, July 12, 2019 - ABB traction technologies to improve rail operator’s energy efficiency and reduce carbon emissionsABB has won orders worth more than $140 million from Swiss train manufacturer, Stadler, to supply state-of-the-art traction equipment for trains and locomotives in the United States and several European countries. The orders were booked in the second quarter of 2019. In the United States, the order includes traction converters for 19 double-deck trains for Caltrain to meet projected increase in travel demand in the San Francisco Bay Area. The new trains

ProfilGruppen has appointed Fredrik Zöögling to CEO and President

ProfilGruppen AB has appointed Fredrik Zöögling as CEO and President with start from January 10, 2020 at the latest. Fredrik Zöögling, Master of Engineering, 53 years old, has long-standing experience from leading industry positions, most recently as CEO of Eberspächer Exhaust Technology AB. The company manfactures and sells exhaust systems for the automotive industry and has about 900 employees with a turnover of about MSEK 3,600. Fredrik has earlier been working in several different companies, mainly acting assub suppliers to the automotive industry. In accordance with the press

SKF extends sponsorship of Gothia Cup

Gothenburg, 12 July 2019: SKF has extended its sponsorship of Gothia Cup. SKF will continue as main partner for the world’s largest youth football tournament, which takes place every summer in Gothenburg. SKF has been involved with Gothia Cup since 2006, becoming main partner in 2007. The new sponsorship agreement means SKF will continue as main partner until 2022. In addition to being main partner, SKF will continue with its SKF Meet the World tournaments. Through local qualifying tournaments, SKF Meet the World gives children from different backgrounds the opportunity to travel to

Q-linea strengthens management team

UPPSALA, Sweden, 12 July, 2019 - Q-linea AB (publ) (Nasdaq Stockholm:QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, today announced MD Tiziana Di Martino has been appointed the company’s Chief Medical Officer and will be part of Q-linea’s management team.“I am pleased to welcome Tiziana Di Martino to the Q-linea-family. In her previous roles she has successfully managed clinical projects related to new product launches. Her experience will be a great benefit for Q-linea in our present position with our

Triton to acquire Aleris

Stockholm (Sweden) 12 July 2019 – Funds advised by Triton (“Triton“) have signed an agreement to acquire the larger part of the company commonly referred to as Aleris (“Aleris”), through the legal entities Aleris Healthcare AB and Aleris Imaging AB.Aleris is one of the leading healthcare companies in the Nordics and a wholly-owned subsidiary of Patricia Industries, a part of Investor AB. Patricia Industries acquired Aleris in 2010. Tritons´ acquisition does not include the entity Doctor24.  The transaction is subject to regulatory approval. Patient care and daily operations of the

Interim report, January – June 2019

PERIOD APRIL 1 – JUNE 30, 2019 · Net sales of SEK 101.5 m (SEK 100.0 m) · Software revenues of SEK 71.6 m (SEK 66.1 m) · Recurring revenues of SEK 60.0 m (SEK 54.7 m), which corresponds to 59 % (55 %) of net sales. · EBITDA SEK 25.0 m; 24.6 % (SEK 21.5 m; 21.5 %) · EBITDA-adj. SEK 15.9 m; 15.7 % (SEK 13.4 m; 13.4 %) · EBIT SEK 11.5 m; 11.3 % (SEK 9.6 m; 9.6 %) · Net profit SEK 8.4 m; 8.3 % (SEK 7.3 m; 7.3 %) · EPS before dilution SEK 0.16 (SEK 0.14) · Cash flow from operating activities SEK 6.7 m (SEK 20.9 m) PERIOD JANUARY 1 – JUNE 30, 2019 · Net sales

Beijer Ref AB Q2-2019

Continued strong growthNet sales increased by 14% in the second quarter compared to the same period last year and amounted to SEK 3,996 million (3,510). Organic growth was 4.4%. The operating profit for the quarter amounted to SEK 373 million (345), an increase of 8% compared with the same period last year. The operating margin was 9.3% (9.8%), of which 0.2% is a positive IFRS 16 effect. Profit for the period totalled SEK 265 million (255). Profit per share amounted to SEK 2.08 (1.98). The company's liquidity is good and unutilised credit amounts to SEK 1427 million (393). With

Interim report January – June 2019: High growth and good profitability

Second quarter: · Sales amounted to SEK 381 (283) million, corresponding to an increase of 34 percent in SEK. Sales increased by 29 percent in local currency whereof 18 percent comprised organic growth. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 146 (116) million, corresponding to a margin of 38 (41) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 7 million. · Net income amounted to SEK 95 (80) million, which gave earnings per share of SEK 0.87 (0.73). · Acquisition and collaboration agreement regarding technology

Notice to attend the extraordinary general meeting in Speqta AB (publ)

The shareholders of Speqta AB (publ), reg.no. 556710-8757, (the “Company”), are hereby given notice to attend the extraordinary general meeting, held at 10:00 a.m. on 13 August 2019 at Advokatfirman Delphi, Mäster Samuelsgatan 17, in Stockholm.Notice of participation Shareholders wishing to participate at the extraordinary general meeting shall: -        be registered in the share register maintained by Euroclear Sweden AB on Wednesday 7 August 2019, and -        notify the Company of their and any proxies participation, either in writing to Speqta AB (publ), Regeringsgatan 29, 111

Interim report January to June 2019

Outlining the new TagMaster Second quarter · Net sales increased during the second quarter by 4,8 % to 53,2MSEK (50,7) · Result before depreciation (EBITDA) for the second quarter amounted to 0,0 MSEK (3,4), corresponding to a margin of 0,0% (6,7) · Net result after tax was -3,3 MSEK (0,8) · Result per share was -0,01 (0,00) · Cash flow from the business for the period was -0,2 MSEK (11,6) · The acquisition of Sensys Networks was completed on June 13. The purchase price was USD 16 million on a debt and cash free basis with adjustment of net working capital as of the

Digital dentistry has revolutionised dental surgery

Dr. Zach Evans is a periodontist and Assistant Professor at the Medical University of South Carolina. After starting out performing dental surgery free-hand, he switched to surgical guides and has not looked back. Dr. Evans now uses the Planmeca Romexis® 3D Implant Guide software daily and says he could not live without it. Dr. Zach Evans is a well-respected periodontist and an internationally renowned lecturer, who discovered his passion for dentistry while he was working towards his PhD in Biomedical Science. He realised that in order to become successful he needed and wanted

Report and presentation for the second quarter 2019

Financial and operating highlights 2Q19 (2Q18 in brackets): · Operating revenues were NOK 2 023 million (NOK 1 662 million) · EBITDA was NOK 511 million (NOK 350 million) · EBIT was NOK 271 million (NOK 95 million) · Net result after tax from continuing operations was NOK -11 million (NOK -26 million) Segment highlights 2Q19 (2Q18 in brackets): Renewable energy · EBITDA NOK 111 mill. (NOK 165 mill.) · Total generation down 3% · Year on year decreasing electricity prices in all markets Shipping / Offshore wind · EBITDA NOK 255 mill. (NOK 64 mill.) ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top